Saba Capital Management, L.P. Acquires 10,986 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock

Abrdn Life Sciences Investors (NYSE:HQLGet Free Report) major shareholder Saba Capital Management, L.P. purchased 10,986 shares of the firm’s stock in a transaction dated Wednesday, May 8th. The stock was acquired at an average price of $13.70 per share, with a total value of $150,508.20. Following the purchase, the insider now directly owns 3,140,590 shares of the company’s stock, valued at $43,026,083. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

  • On Monday, May 6th, Saba Capital Management, L.P. acquired 10,713 shares of Abrdn Life Sciences Investors stock. The stock was acquired at an average price of $13.62 per share, with a total value of $145,911.06.
  • On Thursday, May 2nd, Saba Capital Management, L.P. bought 26,274 shares of Abrdn Life Sciences Investors stock. The stock was acquired at an average cost of $13.46 per share, with a total value of $353,648.04.
  • On Tuesday, April 30th, Saba Capital Management, L.P. purchased 16,573 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average price of $13.13 per share, with a total value of $217,603.49.
  • On Friday, April 26th, Saba Capital Management, L.P. acquired 120,304 shares of Abrdn Life Sciences Investors stock. The shares were bought at an average price of $13.00 per share, for a total transaction of $1,563,952.00.
  • On Wednesday, April 24th, Saba Capital Management, L.P. bought 20,529 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average cost of $13.12 per share, with a total value of $269,340.48.
  • On Monday, April 22nd, Saba Capital Management, L.P. purchased 2,022 shares of Abrdn Life Sciences Investors stock. The shares were purchased at an average cost of $12.88 per share, for a total transaction of $26,043.36.
  • On Thursday, April 18th, Saba Capital Management, L.P. acquired 81,738 shares of Abrdn Life Sciences Investors stock. The shares were purchased at an average price of $12.80 per share, with a total value of $1,046,246.40.

Abrdn Life Sciences Investors Price Performance

Shares of NYSE:HQL opened at $13.85 on Friday. The stock’s 50-day simple moving average is $13.40 and its two-hundred day simple moving average is $13.21. Abrdn Life Sciences Investors has a 52-week low of $11.34 and a 52-week high of $14.37.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Oppenheimer & Co. Inc. boosted its holdings in shares of Abrdn Life Sciences Investors by 4.6% in the first quarter. Oppenheimer & Co. Inc. now owns 18,414 shares of the company’s stock worth $251,000 after buying an additional 814 shares during the last quarter. Kingsview Wealth Management LLC boosted its holdings in shares of Abrdn Life Sciences Investors by 2.5% in the fourth quarter. Kingsview Wealth Management LLC now owns 36,937 shares of the company’s stock worth $497,000 after buying an additional 904 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Abrdn Life Sciences Investors by 1.7% in the third quarter. Janney Montgomery Scott LLC now owns 72,249 shares of the company’s stock worth $901,000 after buying an additional 1,220 shares during the last quarter. Shaker Financial Services LLC boosted its holdings in shares of Abrdn Life Sciences Investors by 2.1% in the third quarter. Shaker Financial Services LLC now owns 66,528 shares of the company’s stock worth $830,000 after buying an additional 1,342 shares during the last quarter. Finally, Future Financial Wealth Managment LLC purchased a new position in shares of Abrdn Life Sciences Investors in the first quarter worth approximately $27,000. Hedge funds and other institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.

Read More

Insider Buying and Selling by Quarter for Abrdn Life Sciences Investors (NYSE:HQL)

Receive News & Ratings for Abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.